Pharmacological Management of Portal Hypertension and Liver Cirrhosis

Stage-Based Treatment Algorithm

The American Association for the Study of Liver Diseases recommends that non-selective beta-blockers (NSBBs) are the cornerstone of pharmacological treatment for portal hypertension in cirrhotic patients with varices, with carvedilol 12.5 mg/day as the preferred first-line agent due to superior portal pressure reduction compared to traditional NSBBs 1
The European Association for the Study of the Liver suggests that NSBBs should not be initiated in patients with cirrhosis but no varices, as they fail to prevent varix formation and significantly increase serious adverse events without benefit 2, 3, 1
The American College of Gastroenterology recommends focusing exclusively on treating the underlying liver disease, such as alcohol cessation, antiviral therapy for hepatitis B/C, weight loss for NAFLD, or immunosuppression for autoimmune hepatitis, in patients with mild portal hypertension and no varices 3, 4, 1

The American College of Cardiology recommends initiating vasoactive drugs immediately when variceal hemorrhage is suspected, before endoscopy, with options including octreotide, terlipressin, and somatostatin 1, 6, 5
The International Society for Hepatic Surgery suggests temporarily suspending NSBBs if systolic BP <90 mmHg or mean arterial pressure <65 mmHg during acute bleeding 1, 5

The American Association for the Study of Liver Diseases strongly recommends transjugular intrahepatic portosystemic shunt (TIPS) for gastroesophageal variceal bleeding refractory to endoscopic and medical therapy 1, 6
The European Association for the Study of the Liver recommends early/preemptive TIPS within 72 hours in high-risk patients, such as those with Child-Pugh C or MELD ≥19 1, 6, 5

The American College of Gastroenterology lists absolute contraindications for NSBBs, including severe bradycardia, heart block, severe asthma, and decompensated heart failure 1
The International Society for Hepatic Surgery recommends temporarily suspending NSBBs during acute bleeding with systolic BP <90 mmHg or MAP <65 mmHg, and using extreme caution or suspending in refractory ascites with hypotension 1, 5

The American Association for the Study of Liver Diseases recommends targeting hemodynamic response, with HVPG reduction to ≤12 mmHg or ≥20% reduction from baseline, to protect against acute variceal bleeding 6, 5
The European Association for the Study of the Liver suggests monitoring heart rate, blood pressure, and liver function during NSBB therapy, and performing endoscopic surveillance every 2-3 years in compensated cirrhosis and every 1-2 years in decompensated cirrhosis 3, 6

The American College of Cardiology recommends considering liver transplantation in all patients with decompensated cirrhosis, as it is the most effective approach to reduce portal pressure and improve survival 1, 5